MedTrace Logo

FAPI PET for Response Evaluation and Prognosis Prediction in Liver and Biliary Cancer Patients Treated With PD-1 Combination Therapy

NCT05662488 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 25

Last updated 2022-12-22

No results posted yet for this study

Summary

The purpose of this study is to explore the ability of positron emission tomography (PET) with \[68Ga\]FAPI to detect, evaluate treatment response, and predict prognosis in advanced liver and biliary cancer patients treated with anti-PD-1 antibodies-based combination therapy.

Conditions

Interventions

DIAGNOSTIC_TEST

[68Ga]FAPI PET/CT and [18F]FDG PET/CT

To perform \[68Ga\]FAPI PET/CT and \[18F\]FDG PET/CT in patients with advanced liver and biliary cancer before and after treatment with PD-1 Based Combination Therapy

Sponsors & Collaborators

  • Peking Union Medical College Hospital

    lead OTHER

Principal Investigators

  • Li Huo · Peking Union Medical College Hospital

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-01
Primary Completion
2022-08-30
Completion
2023-08-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05662488 on ClinicalTrials.gov